Histone methyltransferases are promising epigenetic drug targets. Several drugs that inhibit histone methyltransferases have been developed for anticancer therapy. DOT1L histone H3 methyltransferase methylates lysine 79 on histone H3 (H3K79), within the globular histone domain upon which DNA is wrapped.
DOT1L is an attractive target for specific malignancies, such as leukemia. Inhibitors of DOT1L could potentially be used for anticancer therapy.
OTAVAchemicals DOT1L Targeted Library (622 compounds)
has been carefully designed with receptor-based approach that included docking of Drug-like Green Collection
in the active site of human DOT1L (crystal structure of complex with inhibitor FED2, PDB ID 4EQZ) and filtering by score values and hydrogen bonds formed between ligand and key residues of the DOT1L active site. The library comprises drug-like compounds only.
All compounds are in stock, cherry-picking is available.
The library (DB, SD, XLS, PDF format) as well as the price-list is available on request. Feel free to contact us or use on-line form below to send an inquiry if you are interested to obtain this library or if you need more information.